Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar in Stable Cardiovascular Disease and Glucose Abnormalities
NCT01715818Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of aleglitazar in cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), sponsored by Roche. Started Dec 2012; status: completed.
02
Drugs
aleglitazar
03
Conditions
cardiovascular disease (CVD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01715818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01715818.